Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b open-label pegvaliase study in adults with uncontrolled phenylketonuria
2018-000648-25Phase 3Completed
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Aug 2018
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegvaliase in phenylketonuria (PKU), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Blood phenylalanine control by Week 60. Started Aug 2018; status: completed.
02
Drugs
pegvaliase
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on 2018-000648-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000648-25.